ClinicalTrials.gg
RecruitingNCT06747949Updated Apr 28, 2026

A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS)

A Phase 3 interventional study of Dazodalibep in Sjögren's Syndrome, sponsored by Amgen. Recruiting at 174 sites in 26 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-28.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2025; still recruiting 1 year 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
844
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 111 studies in Sjogren's Syndrome with a site in United States — 23 open to participants now, 29 under way, 8 of them phase 3. Sjogren's Syndrome · United States.

Planned enrollment
Largest of 76
844 · median 57
Started
2025
with 5 others
Phase 3
12 of 111
3 open now
Primary completion
2029-12
later than 20 of 27 live
Registered
100th of 111
by date
Lead sponsor
7 of 111
Amgen

Among the 111 studies in Sjogren's Syndrome with a site in United States, this one has the largest planned enrollment of the 76 interventional ones that give a count, is one of 6 that started in 2025, is one of 12 in phase 3, reaches primary completion later than 20 of the 27 other live ones, and was the 100th registered.

Sjogren's Syndrome

330 studies on the registry are indexed under Sjogren's Syndrome; 99 are open to participants now.

Browse Sjogren's Syndrome studies →

Open to participants now

23 of the 111 studies in Sjogren's Syndrome with a site in United States are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 67 Sjogren's Syndrome studies recruiting now, 26 (39%) set no upper age limit and 25 (37%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 111 studies in Sjogren's Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the long-term safety and tolerability of dazodalibep.

03

Conditions studied

  • Sjögren's Syndrome

Browse trials for

Keywords

  • Cluster of differentiation 40 (CD40)
  • Dazodalibep
  • AMG 611
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants are eligible to be included in the study only if all the following criteria apply:

  • Participant has provided before initiation of any study specific activities/procedures.
  • Must have been eligible to receive and have received IP (dazodalibep or placebo) and completed the study (through Week 48) in one of the phase 3 SS dazodalibep studies (HZNP-DAZ-301, or HZNP-DAZ-303).
  • Must be able to receive Dose 1 of this LTE study at the Week 48 Visit (+28 days) for the prior pivotal phase 3 SS dazodalibep studies (HZNP DAZ-301, or HZNP DAZ-303).

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • active infection at Day 1, in the opinion of the Investigator, including ongoing and chronic infection requiring antibiotics or antiviral medication.
  • Planned participation in another clinical study with an IP or procedure during the LTE study. Other procedures and participation in observational research studies while participating in this study are excluded.
  • Any condition or change in health status observed or reported during the phase 3 SS studies (HZNP-DAZ-301, or HZNP-DAZ-303) that, in the opinion of the Investigator or the Sponsor, would interfere with evaluation and interpretation of participant safety or alter the risk-benefit associated with IP administration.
  • Planned surgeries or hospitalizations that, in the opinion of the Investigator or the Sponsor, would interfere with evaluation and interpretation of participant safety.
  • Individuals who plan to receive live (attenuated) vaccine during the LTE study.
  • Female participants of unwilling to use protocol-specified method of during treatment and for an additional 12 weeks after the last dose of investigational product.
  • Female participants who are pregnant or lactating or planning to become pregnant during the study.
  • Participant has known sensitivity to any of the products or components to be administered during dosing.
  • Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the participant and investigator's knowledge.
  • History or evidence of any other clinically significant disorder, condition, or disease that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to participant safety or interfere with the study evaluation.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
844 participants (estimated)

Study arms

  • Experimental
    Dazodalibep

    Participants who completed the 48-week dazodalibep or placebo treatment in trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive assigned dose Dose A of dazodalibep for an additional 132 weeks.

    Drug: Dazodalibep

Interventions

  • Dazodalibep will be given intravenously (IV).

    Also known as: AMG 611

06

What researchers measure

Primary outcomes

  1. Number of Participants with Treatment-emergent Adverse Events (TEAEs)

    Includes treatment emergent serious adverse events (TESAEs) and adverse events of special interest (AESIs).

    Time frame: Up to 152 weeks

Secondary outcomes

  1. Number of Participants with Anti-drug Antibodies (ADAs) During the Study

    Time frame: Up to 132 weeks

  2. Plasma Concentration of Dazodalibep

    Time frame: Up to 132 weeks

07

Study locations

174 of 174 sites recruiting
  • Arizona Arthritis & Rheumatology Associates - Avondale
    Avondale, Arizona 85392, United States
    Recruiting
  • Arizona Arthritis and Rheumatology Associates - Flagstaff - 399 S Malpais Ln
    Flagstaff, Arizona 86001-6269, United States
    Recruiting
  • Arizona Arthritis and Rheumatology Associates - Gilbert - 3645 S Rome St
    Gilbert, Arizona 85297-7336, United States
    Recruiting
  • Arizona Arthritis and Rheumatology Associates - Glendale - 5681 W Beverly Ln
    Glendale, Arizona 85306-9800, United States
    Recruiting
  • Arizona Arthritis and Rheumatology Associates - Tucson - 2001 W Orange Grove Rd
    Tucson, Arizona 85704-1139, United States
    Recruiting
  • Samy Metyas MD Inc
    Covina, California 91723, United States
    Recruiting
  • UCSD Altman Clinical and Translational Research Institute Building
    La Jolla, California 92037-1337, United States
    Recruiting
  • Tekton Research, LLC - 2121 E Harmony Rd - PPDS
    Fort Collins, Colorado 80528-3400, United States
    Recruiting
  • Bradenton Research Center Inc
    Bradenton, Florida 34205-1704, United States
    Recruiting
  • Clinical Research of West Florida Inc - Clearwater
    Clearwater, Florida 33765-2616, United States
    Recruiting
  • BayCare Medical Group Primary Care and Rheumatology - Tampa
    Tampa, Florida 33614-7101, United States
    Recruiting
  • Tufts University School of Dental Medicine
    Boston, Massachusetts 02111-1527, United States
    Recruiting
  • Shores Rheumatology
    Saint Clair Shores, Michigan 48081-1274, United States
    Recruiting
  • Kansas City Physician Partners-8350 N Saint Clair Ave
    Kansas City, Missouri 64151, United States
    Recruiting
  • Arthritis, Rheumatic & Bone Disease Associates - Voorhees
    Voorhees Township, New Jersey 08043-4501, United States
    Recruiting
  • Arthritis and Osteoporosis Consultants of The Carolinas - Charlotte - 1918 Randolph Rd
    Charlotte, North Carolina 28207-1100, United States
    Recruiting
  • Duke Early Phase Clinical Research Unit - PPDS
    Durham, North Carolina 27710-0001, United States
    Recruiting
  • Onsite Clinical Solutions, LLC - Salisbury
    Salisbury, North Carolina 28144, United States
    Recruiting
  • Arthritis & Osteoporosis Center of Southwest Ohio - Miamisburg
    Miamisburg, Ohio 45342-3585, United States
    Recruiting
  • University of Toledo Medical Center
    Toledo, Ohio 43614-2595, United States
    Recruiting
  • STAT Research-600 Aviator Ct
    Vandalia, Ohio 45377-9474, United States
    Recruiting
  • Murfreesboro Medical Clinic Westlawn
    Murfreesboro, Tennessee 37128, United States
    Recruiting
  • Accurate Clinical Management-Baytown
    Baytown, Texas 77521-2279, United States
    Recruiting
  • Precision Comprehensive Clinical Research Solutions
    Colleyville, Texas 76034-5913, United States
    Recruiting
  • R & H Clinical Research-777 S Fry Rd
    Katy, Texas 77450-2297, United States
    Recruiting
  • Houston Rheumatology & Arthritis Specialists - PLLC - PPDS
    Katy, Texas 77494-1341, United States
    Recruiting
  • Biopharma Informatic - Ridge Road - PPDS
    McAllen, Texas 78503-1527, United States
    Recruiting
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382-2935, United States
    Recruiting
  • DM Clinical Research - Migraine and COPD - PPDS
    Tomball, Texas 77375, United States
    Recruiting
  • Western Washington Medical Group, Bothell - Rheumatology
    Bothell, Washington 98021, United States
    Recruiting
  • Rheumatology and Pulmonary Clinic
    Beckley, West Virginia 25801-2805, United States
    Recruiting
  • Consultorios Médicos Dr. Doreski - Fundacion Respirar - PPDS
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1426ABP, Argentina
    Recruiting
  • Instituto CER S.A.
    Quilmes, Buenos Aires B1878DVB, Argentina
    Recruiting
  • Instituto de Investigaciones Clinicas Quilmes SRL
    Quilmes, Buenos Aires B1878GEG, Argentina
    Recruiting
  • MR Medicina Reumatologica
    San Fernando, Buenos Aires B1646GHP, Argentina
    Recruiting
  • DOM Centro de Reumatología
    Buenos Aires, Ciudad Autónoma de BuenosAires C1111, Argentina
    Recruiting
  • Centro de Investigaciones Reumatológicas
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
    Recruiting
  • Centro Medico Privado de Reumatologia - PPDS
    San Miguel de Tucumán, Tucumán Province T4000AXL, Argentina
    Recruiting
  • Clínica Mayo de U.M.C.B. S.R.L
    San Miguel de Tucumán, Tucumán Province T4000IHE, Argentina
    Recruiting
  • Aprillus Asistencia e Investigacion - Terrada 89
    Buenos Aires, 1406, Argentina
    Recruiting
  • Hospital General de Agudos Dr. José María Ramos Mejia
    Buenos Aires, C1121ADC, Argentina
    Recruiting
  • Sanatorio Agote - Swiss Medical Group - PPDS
    Buenos Aires, C1425EOE, Argentina
    Recruiting
  • Centro Medico Arsema
    Buenos Aires, C1427CCL, Argentina
    Recruiting
  • Sanatorio Allende S.A.-Hipolito Yrigoyen 384
    Córdoba, X5000JHQ, Argentina
    Recruiting
  • Framingham Centro Médico
    La Plata, B1902COS, Argentina
    Recruiting
  • Centro Polivalente de Asistencia e Investigación Clínica - CER San Juan
    San Juan, J5402DIL, Argentina
    Recruiting
  • The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
    Recruiting
  • UZ Gent
    Ghent, 9000, Belgium
    Recruiting
  • SER - Serviços Especializados em Reumatologia da Bahia S/S - ME
    Salvador, Estado de Bahia 40150-150, Brazil
    Recruiting
  • Centro de Estudos em Terapias Inovadoras
    Curitiba, Paraná 80030-110, Brazil
    Recruiting
  • LMK Servicos Medicos SS
    Porto Alegre, Rio Grande do Sul 90480-000, Brazil
    Recruiting
  • Clinique de Rhumatologie Du Centre Du Quebec
    Trois-Rivières, Quebec G8Z 1Y2, Canada
    Recruiting
  • Centro de Investigacion de Enfermedades Respiratorias e inmunologicas
    Viña del Mar, Valparaiso 2520000, Chile
    Recruiting
  • Enroll SpA - Dr. Manuel Barros Borgono - PPDS
    Providencia, 7500000, Chile
    Recruiting
  • BIOCINETIC Ltda
    Santiago, 8350595, Chile
    Recruiting
  • Centro de especialidades médicas Vanguardia
    Temuco, 4810345, Chile
    Recruiting
  • Clinical Research Chile SpA - PPDS
    Valdivia, 5110683, Chile
    Recruiting
  • Polyclinic Bonifarm
    Zagreb, City of Zagreb 10000, Croatia
    Recruiting
  • University Hospital of Split
    Split, 21000, Croatia
    Recruiting
  • CHU de Bordeaux - Hôpital Saint-André
    Bordeaux, 33000, France
    Recruiting
  • CHU de Brest - Hôpital La Cavale Blanche
    Brest, 29200, France
    Recruiting
  • GHRMSA - Hôpital Emile Muller
    Mulhouse, 68100, France
    Recruiting
  • AP-HP - Hôpital Saint Antoine
    Paris, 75012, France
    Recruiting
  • Hôpitaux Universitaires de Strasbourg
    Strasbourg, 67091, France
    Recruiting
  • University Clinic Heidelberg
    Heidelberg, Baden-Wurttemberg 69120, Germany
    Recruiting
  • Rheumazentrum Prof. Dr. med. Gunther Neeck-Standort Bad Doberan
    Bad Doberan, Mecklenburg-Vorpommern 18209, Germany
    Recruiting
  • Rheumazentrum Greifswald
    Greifswald Hansestadt, Mecklenburg-Vorpommern 17493, Germany
    Recruiting
  • MVZ Rheuma
    Hamburg, 20095, Germany
    Recruiting
  • Naval Hospital of Athens
    Athens, Attica 115 21, Greece
    Recruiting
  • Laiko General Hospital of Athens
    Athens, Attica 115 27, Greece
    Recruiting
  • University General Hospital of Larissa
    Larissa, Larisa 411 10, Greece
    Recruiting
  • Euromedica Kianous Stavros
    Thessaloniki, 546 36, Greece
    Recruiting
  • Bekes Varmegyei Kozponti Korhaz
    Gyula, Bekes County 5700, Hungary
    Recruiting
  • Vasarhelyi Sarkanyfu Kft.
    Hódmezovásárhely, Csongrád megye 6800, Hungary
    Recruiting
  • Debreceni Egyetem Klinikai Kozpont Nagyerdei Campus
    Debrecen, Hajdú-Bihar 4032, Hungary
    Recruiting
  • Del-pesti Centrumkorhaz- Orszagos Hematologiai és Infektologiai Intezet - Albert Flórián út 5-7
    Budapest, 1097, Hungary
    Recruiting
  • Meir Medical Center
    Kafr Saba, Central District 4428164, Israel
    Recruiting
  • The Chaim Sheba Medical Center - PPDS
    Ramat Gan, Tel Aviv 5262100, Israel
    Recruiting
  • Azienda Sanitaria Universitaria Friuli Centrale - PO Universitario Santa Maria della Misericordia
    Udine, Friuli Venezia Giulia 33100, Italy
    Recruiting
  • Fondazione Policlinico Universitario A Gemelli - Rome - PPDS
    Rome, Lazio 00168, Italy
    Recruiting
  • Fondazione Policlinico Universitario Campus Bio-Medico
    Rome, Lazio 128, Italy
    Recruiting
  • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, Lombardy 20122, Italy
    Recruiting
  • A.O.U. Città della Salute e della Scienza di Torino
    Turin, Piedmont 10126, Italy
    Recruiting
  • Azienda Ospedaliera Universitaria Integrata Di Verona
    Verona, Veneto 37126, Italy
    Recruiting
  • Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara
    Pisa, 56126, Italy
    Recruiting
  • AUSL di Reggio Emilia - IRCCS - Arcispedale Santa Maria Nuova
    Reggio Emilia, 42123, Italy
    Recruiting
  • Chubu Rosai Hospital
    Nagoya-shi, Akita 455-0018, Japan
    Recruiting
  • Japan Community Health Care Organization (JCHO) Chukyo Hospital
    Nagoya-shi, Akita 457-0866, Japan
    Recruiting
  • Daido Clinic
    Nagoya, Akita 457-8511, Japan
    Recruiting
  • Sapporo Medical University Hospital
    Sapporo, Hokkaidô 060-8543, Japan
    Recruiting
  • Hokkaido University Hospital
    Sapporo, Hokkaidô 060-8648, Japan
    Recruiting
  • Hospital of the University of Occupational and Environmental Health, Japan
    Kita Kyushu-shi, Hukuoka 807-8556, Japan
    Recruiting
  • University of Tsukuba Hospital
    Tsukuba, Ibaraki 305-8576, Japan
    Recruiting
  • Kanazawa Medical University Hospital
    Kahoku, Ishikawa-ken 920-0293, Japan
    Recruiting
  • Kanazawa University Hospital
    Kanazawa, Ishikawa-ken 920-8641, Japan
    Recruiting
  • National Hospital Organization Yokohama Medical Center
    Yokohama, Kanagawa 245-8575, Japan
    Recruiting
  • University Hospital, Kyoto Prefectural University of Medicine
    Kyoto, Kyôto 602-8566, Japan
    Recruiting
  • Kyoto University Hospital
    Kyoto, Kyôto 606-8507, Japan
    Recruiting
  • Nagasaki University Hospital
    Nagasaki, Nagasaki 852-8501, Japan
    Recruiting
  • Sasebo Chuo Hospital
    Sasebo-Shi, Nagasaki 857-1165, Japan
    Recruiting

Showing the first 100 of 174 sites across 26 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.

Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code were provided in analysis specifications. Further details are available at the URL below.

Data sharing details ↗ · www.amgen.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2025 (actual). Primary completion is estimated for Dec 2029, 57 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2024
First posted
Dec 24, 2024
StartActual
Feb 25, 2025
Primary completionEst.
Dec 11, 2029
CompletionEst.
Dec 11, 2029
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747949
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Feb 25, 2025
Primary completion
Dec 11, 2029 (estimated)
Completion
Dec 11, 2029 (estimated)
Last update
Apr 28, 2026

Study contacts

Amgen Call Center
Contact
medinfo@amgen.com
866-572-6436
MD
study director · Amgen

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dazodalibep

Start the discussion